XTL - SPDR S&P Telecom ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
68.68
-0.05 (-0.07%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close68.73
Open68.60
Bid66.21 x 100
Ask0.00 x 0
Day's Range68.67 - 69.22
52 Week Range65.10 - 74.64
Volume7,130
Avg. Volume8,831
Net Assets45.95M
NAV70.69
PE Ratio (TTM)N/A
Yield1.55%
YTD Return2.97%
Beta (3y)0.97
Expense Ratio (net)0.35%
Inception Date2011-01-26
Trade prices are not sourced from all markets
  • Telecommunications ETF Investing Guide
    Zacks9 days ago

    Telecommunications ETF Investing Guide

    Major telecommunications stocks did well in the third quarter, what lies ahead?

  • PR Newswire12 days ago

    XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements

    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has received notification from the NASDAQ Stock Market LLC ("NASDAQ") that the Company has regained compliance with the minimum $2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market. As previously disclosed, on October 17, 2017, the Company received a notice from NASDAQ stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Rule") because the Company did not have a minimum stockholders' equity, as of June 30, 2017, of $2.5 million and the Company did not alternatively meet the market capitalization or income from continuing operations tests.

  • ETF Databaselast month

    ETF Scorecard: November 3 Edition

    To help investors keep up with the markets, we present our ETF Scorecard. The Scorecard takes a step back and looks at how various asset classes across the globe are performing. The weekly performance is from last Friday’s open to this week’s Thursday close.

  • ETF Database2 months ago

    ETF Scorecard: October 20 Edition

    To help investors keep up with the markets, we present our ETF Scorecard. The Scorecard takes a step back and looks at how various asset classes across the globe are performing. The weekly performance is from last Friday’s open to this week’s Thursday close.

  • Barrons.com2 months ago

    In a Flat Market, Sector Picking Will Reap Rewards

     Although the S&P 500 has been on a tear this year, and hit another new high yesterday, Societe Generale’s Alain Bokobza and his team don’t see that streak continuing, projecting a 2,450 close this year and 2,500 for year-end 2018. More detail from  his note: Clear impact of Treasury yield on US sector performance, less obvious for US dollar: A bivariate analysis (versus the dollar and the level of rates using quarterly data from 2007 onwards) looks less compelling graphically. In materials, for example, the negative sensitivity to the dollar index is clearly visible, but it seems to be trumped by the sensitivity to higher yields, leading to a predominant outperformance in the upper right quadrant.

  • Market Realist4 months ago

    Will the S&P 500 Index Recover from Last Week’s Fall?

    The S&P 500 Index (SPY) closed last week at 2425.55, losing 0.65% as compared to its August 11 close.

  • Zacks4 months ago

    What Like Ahead for Telecom ETFs?

    We expect this industry to witness growth more or less in line with the broader market.

  • 5 Top Telecom ETFs
    Motley Fool5 months ago

    5 Top Telecom ETFs

    If you like telecom stocks, these funds have what you want.

  • Can Stock Market Keep Rising As Summer Doldrums Loom?
    Investor's Business Daily7 months ago

    Can Stock Market Keep Rising As Summer Doldrums Loom?

    Telecom, biotech and retail ETFs outperformed early Thursday as the market kicked off June with narrow gains.

  • PR Newswire8 months ago

    XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors

    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that Mr. Alex Rabinovich has been appointed as a member of the Company's board of directors. Mr. Rabinovich is a leading investor in XTL and holds over 20% of its shares. Mr. Rabinovich will replace Mr. David Bassa, who has resigned from his position as a director of the Company, after serving as a director for seven years.

  • PR Newswire8 months ago

    XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome

    RAANANA, Israel, April 5, 2017 /PRNewswire/ -- Additional data shows a statistically significant effect in the gene expression of two additional genes that have a role in the pathogenesis of Sj ö gren ...

  • PR Newswire9 months ago

    XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors

    XTL Biopharmaceuticals Ltd. (XTLB) (XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has closed its private offering of securities for proceeds of $2.8 million. In connection with the offering, announced previously on March 7, 2017, the Company issued and sold 1,400,000 American Depository Shares (ADSs) at a purchase price of $2.00 per ADS. The Company has agreed to hold a shareholder meeting to increase its authorized ordinary shares to allow for the full exercise of the warrants (the "Authorized Capital Increase").

  • Zacks9 months ago

    5 Biggest Winners from the Fed Rate Hike

    The Fed dropped hints that it will not raise rates four times this year, a definite loss for the Wall Street and a win for the Main Street.

  • PR Newswire10 months ago

    XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement

    As previously disclosed on November 14, 2017, XTL received a letter from Nasdaq notifying the Company that it was not in compliance with Nasdaq's Listing Rule 5450(a)(1) because the minimum bid price of the Company's American Depositary Shares ("ADSs") had closed below US $1.00 per share for 30 consecutive business days. On February 28, 2017, XTL received notification from Nasdaq that the closing price of the Company's America Depository Share has been at $1.00 per share or greater for the last 10 consecutive business days from February 10 through 24, 2017.

  • PR Newswire10 months ago

    XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome

    RAANANA, Israel, February 13, 2017 /PRNewswire/ -- Dr. Robert   I.   Fox and   Professor   Simon Bowman   are   world-renowned   rheumatologists and experts in Sjogren's syndrome     XTL Biopharmaceuticals ...

  • Zacks10 months ago

    Telecom ETFs: What Lies Ahead in 2017?

    The U.S. telecommunications industry is likely to witness reasonable growth through 2017.

  • ETFs That Sound Alike Are Often Different
    ETF.com11 months ago

    ETFs That Sound Alike Are Often Different

    What stocks should you expect to find in a European ETF? How about a homebuilder ETF? While these questions should not be hard to answer, what’s inside an ETF might surprise you and your clients. CFRA’s ETF research is based in part on the belief that an ETF is a basket of securities. So rather than judging an ETF using a rearview mirror approach, which can result in whiplash, we review the underlying holdings. The constituents of similar-sounding ETFs will be distinct, which impacts performance.

  • PR Newswire11 months ago

    XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program

    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced the Company has authorized The Bank of New York Mellon, as depository ("BNY Mellon"), to effect on February 10, 2017 a change in the ratio from one (1) Depositary Share ("DS") representing twenty (20) ordinary shares to a new ratio of one (1) DS representing one hundred (100) ordinary shares. For the Company's DS holders, this ratio change will have the same effect as a reverse split on the XTL DSs on the basis of one (1) new DS for every five (5) old DSs held.

  • PR Newswirelast year

    XTL Biopharmaceuticals to Present at Biotech Showcase

    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead product for the treatment of lupus and other autoimmune diseases, today announced the Company's Chief Executive Officer, Josh Levine, will present at Biotech Showcase on Wednesday, January 9-11, 2017 at 3:30 pm PT in San Francisco. XTL's presentation will include an overview and the latest updates on the Company's lead compound, hCDR1, in development for the treatment of Systemic Lupus Erythematosus (SLE) and other autoimmune diseases.